Improvement in Schirmer test score observed with Tyrvaya treatment

July 12, 2022

1 minute watch


Healio Interviews

Katz does not report any relevant financial information.

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

WASHINGTON – In this Healio video perspective from the American Society of Cataract and Refractive Surgery meeting, James A. Katz, M.D, deals with dry eye research that focuses on a patient’s overall well-being rather than just one eye.

Katz said that for a patient to feel better overall, both eyes need to be treated. In a study of nearly 900 participants, Tyrvaya (Varenicline Solution, Oyster Point Pharma) showed significant improvement in mean Schirmer test score as well as clinically significant improvement in the other eye.

Katz OG

Comments are closed.